Annual Meeting: New Treatment (T-DM1) for HER2-Positive Advanced Breast Cancer?

feeds has 409 videos Subscribe Here

Description: "A phase III randomized study of the investigational agent trastuzumab emtansine (T-DM1) versus standard therapy using capecitabine (Xeloda) and lapatinib (Tykerb) found significant and clinically meaningful improvement in progression-free survival (PFS) for T-DM1 in women with HER2-positive locally advanced or metastatic breast cancer previously treated with a taxane and trastuzumab," according to a news release. Lead author, Dr. Kimberly Blackwell, discusses the findings. For more, visit http://www.oncologypractice....
Shared By : feeds
Posted on : 10/02/12
Added : 7 years ago
Category : News